hackint0sh/New-Dataset huggingface dataset:
This study's main goal is to observe the clinical and angiographic outcomes of drug-coated balloon angioplasty after native coronary lesions that have been successfully revascularized. A few specific goals are to evaluate angiographic results (like percentage diameter stenosis, vascular remodelling, restenosis, and thrombosis) after DCB angioplasty and to assess clinical outcomes (like worsening angina, target vessel MI, ischemia-driven TLR, and cardiac mortality).
The purpose of this study is to give useful insights into the clinical and angiographic results of DCB angioplasty in Bangladeshi patients with native coronary lesions, including the growing body of knowledge on the efficacy and safety of this therapeutic strategy in specific populations. conditions: Coronary Artery Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 303 type: ESTIMATED name: DCB Angioplasty measure: CCS (Canadian Cardiovascular Society) Class of Worsening angina of each participant measure: Number of participants with target vessel Myocardial infarction measure: Ischemia-driven Target lesion revascularization (TLR) each participant measure: Occurrence of Cardiac death in the participants measure: Site of the lesion measure: Lesion Length measure: % of Stenosis measure: Thrombolysis in Myocardial Infarction (TIMI) Flow measure: Pre dilatation - Balloon Type sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Institute of CardioVascular Diseases status: RECRUITING city: Dhaka zip: 1207 country: Bangladesh name: Sayeedur Rahman Khan, MD role: CONTACT phone: +8801711850078 email: dr.rumibd@gmail.com name: Md Zahid Hasan, MD role: CONTACT phone: +8801723-218955 email: zhasan390@gmail.com name: Prof. Mohsin Ahmed, MD role: PRINCIPAL_INVESTIGATOR name: Dr. Sayeedur Rahman Khan, MD role: SUB_INVESTIGATOR name: Dr. Md Zahid Hasan, MD role: SUB_INVESTIGATOR name: Dr. Shariful Islam, MD role: SUB_INVESTIGATOR name: Dr. CM Kudrat E Khuda, MD role: SUB_INVESTIGATOR name: Dr. Mohammad Arifur Rahman, MD role: SUB_INVESTIGATOR name: Dr. Md Matiur Rahman, MD role: SUB_INVESTIGATOR name: Dr. SA Shiblee, MPH role: SUB_INVESTIGATOR name: Md. Habibur Rahman, M.Sc role: SUB_INVESTIGATOR lat: 23.7104 lon: 90.40744 hasResults: False
nctId: NCT06340360 id: 23-358-06 id: 2023-509981-39 type: EUDRACT_NUMBER briefTitle: A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) overallStatus: RECRUITING date: 2024-03-27 date: 2025-08-31 date: 2026-02 date: 2024-04-01 date: 2024-04-03 name: Nektar Therapeutics class: INDUSTRY briefSummary: This is an interventional, randomized, double blind, parallel group, placebo-controlled, Phase 2b, 3-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with severe to very severe alopecia areata.
The estimated duration includes a screening period of up to 35 days, a 36-week treatment period, and a 24-week follow-up period. The maximum study duration is approximately 65 weeks for all participants. conditions: Alopecia Areata studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Patients will be randomized to 1 of 3 groups (low dose, high dose, or placebo). primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 110 type: ESTIMATED name: Rezpegaldesleukin name: Placebo measure: Percent change from baseline in Severity of Alopecia Tool (SALT) score at Week 36 measure: Percent change from baseline in SALT score measure: Proportion of patients achieving improvement in Severity of Alopecia Tool (SALT) ≥ 50%/75%/90% measure: Proportion of patients achieving an absolute SALT score ≤ 10/20/30 sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Austin Institute for Clinical Research status: RECRUITING city: Pflugerville state: Texas zip: 786660 country: United States lat: 30.43937 lon: -97.62 hasResults: False
nctId: NCT06340347 id: C5351010 briefTitle: A Study to Learn How the Body Processes the Study Medicine Called Osivelotor (PF-07940367) in People With Loss of Liver Function overallStatus: NOT_YET_RECRUITING date: 2024-04-24 date: 2026-02-05 date: 2026-02-05 date: 2024-04-01 date: 2024-04-01 name: Pfizer class: INDUSTRY briefSummary: The purpose of this study is to understand how Osivelotor is processed in people with loss of liver function.
Participants will take part in the study for a maximum of 112 days. During this time, participants will have to stay onsite for 5 days. There will be 5 study visits at the study clinic. conditions: Liver Diseases studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: An open label, single dose, parallel cohort study primaryPurpose: BASIC_SCIENCE masking: NONE count: 16 type: ESTIMATED name: Osivelotor measure: Area under the whole blood and plasma concentration versus time curve (AUC) from time zero (pre-dose) to the last quantifiable concentration (AUClast) of osivelotor measure: Area under the whole blood and plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (AUCinf) of osivelotor measure: Maximum observed whole blood and plasma concentration (Cmax) of osivelotor measure: Number of Participants With Treatment-Emergent Adverse Events (AEs) measure: Number of Participants With Clinically Significant Laboratory Abnormalities measure: Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings measure: Number of Participants With Clinically Significant With Clinically Significant Vital Signs sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06340334 id: KY20240123-05 briefTitle: Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-12-31 date: 2024-12-31 date: 2024-04-01 date: 2024-04-01 name: Nanjing First Hospital, Nanjing Medical University class: OTHER briefSummary: To compare the efficacy and safety of Tegoprazan-amoxicillin dual therapy and bismuth quadruple therapy based on furazolidone in the treatment of Helicobacter pylori eradication, the eradication rate, patient compliance, and adverse drug reactions of H. pylori infection were compared in a multi-center clinical joint study in Jiangsu Province. conditions: Helicobacter Pylori Infection conditions: Tegoprazan conditions: Furazolidone studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 600 type: ESTIMATED name: Tegoprazan-amoxicillin dual therapy measure: Helicobacter pylori eradication rate measure: Security observations measure: Patient compliance sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06340321 id: PBRC 2023-081 briefTitle: Impact of Metabolic Flexibility on Changes in Metabolic Health acronym: METPROS overallStatus: ENROLLING_BY_INVITATION date: 2024-06 date: 2025-01 date: 2025-01 date: 2024-04-01 date: 2024-04-03 name: Pennington Biomedical Research Center class: OTHER briefSummary: Metabolic flexibility is the capacity to adapt fuel oxidation to fuel availability so that ATP synthesis can match its cellular demands. Thus, for example, increases in glucose availability after a meal would increase glucose oxidation, while increases in lipid availability during fasting would increase lipid oxidation. Enhanced metabolic flexibility has been proposed to protect humans from metabolic diseases. Nevertheless, most studies examining associations between metabolic flexibility and metabolic health outcomes have used cross-sectional designs. Whether impaired metabolic flexibility causes or results from metabolic health impairment is thus unclear.
In this study, the investigators will use the data from a study conducted approximately 16 years ago in healthy participants without obesity. Using the data already collected in that study, the metabolic flexibility of each participant will be calculated. To test the association between metabolic flexibility and the change in metabolic health, the investigators will call back all the participants for a single follow-up visit to reassess several metabolic health outcomes. Thus, the main aim of the study is to test the association between metabolic flexibility and the change in metabolic health outcomes after 16 years in humans. conditions: Obesity conditions: Metabolic Syndrome studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 88 type: ESTIMATED name: Metabolic flexibility in the fasted state name: Metabolic flexibility in euglycemic-hyperinsulinemic clamp name: Metabolic flexibility in the metabolic chamber measure: Glucose measure: Total cholesterol measure: HDL cholesterol measure: LDL cholesterol measure: Triglycerides measure: HOMA-IR measure: Blood pressure measure: Waist circumference measure: Body mass index measure: Body fat percentage sex: ALL minimumAge: 20 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Pennington Biomedical Research Center city: Baton Rouge state: Louisiana zip: 70808 country: United States lat: 30.45075 lon: -91.15455 hasResults: False
nctId: NCT06340308 id: PARAF 986117570 briefTitle: Clinical Study With Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol acronym: PARAF overallStatus: RECRUITING date: 2023-06-07 date: 2024-03 date: 2024-05 date: 2024-04-01 date: 2024-04-01 name: University of Pavia class: OTHER name: Foundation IRCCS San Matteo Hospital briefSummary: To evaluate the effects of a nutraceutical containing Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol on lipid profile conditions: Dyslipidemias studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 36 type: ESTIMATED name: Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol name: Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol measure: Variations of lipid profile sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Policlinico S. Matteo Foundation status: RECRUITING city: Pavia zip: 27100 country: Italy name: Giuseppe Derosa, MD, PhD role: CONTACT email: giuseppe.derosa@unipv.it name: Pamela Maffioli, MD role: CONTACT email: p.maffioli@smatteo.pv.it name: Giuseppe Derosa, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Pamela Maffioli, MD role: SUB_INVESTIGATOR lat: 45.19205 lon: 9.15917 hasResults: False
nctId: NCT06340282 id: MOTOMED briefTitle: Immersive Virtual Reality and Physical Exercise on Cognitive and Functional Performance in Hospitalized Older Patients acronym: MOTOMED overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-04-01 date: 2025-04-01 date: 2024-04-01 date: 2024-04-03 name: Fundacion Miguel Servet class: OTHER briefSummary: This study will be conducted in a hospital in Spain to investigate how a special intervention using immersive virtual reality technology can benefit hospitalized older adults with difficulties in their daily functionality.
This study aims to provide new insights into the care of hospitalized older adults and explore innovative ways to improve their well-being during their hospital stay conditions: Disability Physical conditions: Cognition studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This clinical randomized controlled trial will be conducted in the Acute Geriatric Unit of a tertiary hospital in Spain. A total of 212 acute patients will be enrolled according to the following criteria: age \> 75, Barthel Index \< 60, able to collaborate, expected length of stay \> 5 days, absence of clinical instability and severe dementia (GDS 7) or other end-stage disease. Patients will be randomly assigned to a control group (CG) or any of the three intervention groups (IG): IVR, ME, or IVR + ME. The IVR group will watch ad-hoc videos showing Spanish regional landscapes and villages, approximately 4 minutes per day for three consecutive days. The ME group will undergo aerobic and strength exercise for progressive training of the upper and lower limbs. The IVR + ME group will do both cognitive and physical intervention. The primary outcomes will be cognitive and physical measures at discharge. Mood, quality of life, isometric strength, and acceptance of IVR will be also assessed. primaryPurpose: PREVENTION masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 212 type: ESTIMATED name: Virtual reality name: multicomponent exercise measure: Mini-Mental State Examination (MMSE) measure: Isometric handgrip strength sex: ALL minimumAge: 75 Years stdAges: OLDER_ADULT hasResults: False
nctId: NCT06340269 id: PJ2308-0025 briefTitle: Feasibility Pilot Study to Evaluate the Safety and Performance of the MEX-CD1 Medical Device in ACLF acronym: MexACLF overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-03 date: 2025-03 date: 2024-04-01 date: 2024-04-03 name: Mexbrain class: INDUSTRY briefSummary: The goal of this clinical trial is to test the MEX-CD1 hemodialysis medical device in patients suffering from ACLF. The main questions it aims to answer are:
Patients will receive 3 MEX-CD1 Slow Low volume CVVHD within 1 week. conditions: Acute on Chronic Liver Failure conditions: Multiple Organ Failure studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Prospective, national, monocentric, single-arm, open label, feasibility pilot clinical trial. primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: MEX-CD1 Dialysis measure: SADE for Safety purpose measure: SAE for Safety purpose measure: Performance of MEX-CD1 measure: Change in Acute on Chronic Liver Failure (ACLF) Grade measure: Change in CLIF-C ACLF score measure: Improvement in individual organ function measure: Development of secondary infection measure: Status of ICU measure: hospital discharge measure: Mortality sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hôpital Croix Rousse, Service d'hépatologie et gastroentérologie city: Lyon state: Rhône-Alpes zip: 69317 country: France name: Céline GUICHON, MD role: CONTACT phone: +33426109351 email: celine.guichon@chu-lyon.fr name: Céline Guichon, MD role: PRINCIPAL_INVESTIGATOR lat: 45.74848 lon: 4.84669 hasResults: False
nctId: NCT06340256 id: IRB0000871253 briefTitle: Continuous Spinal Anesthesia Versus Epidural Anesthesia in Geriatric overallStatus: COMPLETED date: 2021-09-18 date: 2023-08-02 date: 2023-08-15 date: 2024-04-01 date: 2024-04-01 name: Assiut University class: OTHER briefSummary: 60 patients aged older than 60 years, American Society of Anesthesiologists (ASA) class II or III and scheduled for major hip surgery will be randomized, in to two groups anesthetized using continuous spinal anesthesia or using continuous epidural anesthesia. conditions: Epidural Catheter studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: SINGLE whoMasked: PARTICIPANT count: 60 type: ACTUAL name: Continuous spinal anesthesia name: Continuous epidural anesthesia measure: Hemodynamic changes measure: Patient satisfaction sex: ALL minimumAge: 60 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Al-Azhar Faculty of Medicine city: Assiut country: Egypt lat: 27.18096 lon: 31.18368 hasResults: False
nctId: NCT06340243 id: HODGKIN briefTitle: Risk Adapted Therapy of Hodgkin Lymphoma in Upper Egypt overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-04-01 date: 2026-04-01 date: 2024-04-01 date: 2024-04-01 name: Assiut University class: OTHER briefSummary: determine if radiotherapy could be safely omitted for early hodgkin lymphoma responder patients without compromising outcome conditions: Pediatric Hodgkin Lymphoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: radiotherapy measure: assess the outcome of pediatric patients with HL treated with risk- and response-adjusted therapy sex: ALL minimumAge: 1 Month maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06340230 id: BC-NEO-IIT-SHR-A1811-SHR1316 briefTitle: SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in ER Positive/HER2 Low Breast Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2026-02-28 date: 2031-02-28 date: 2024-04-01 date: 2024-04-01 name: Shengjing Hospital class: OTHER name: Jiangsu HengRui Medicine Co., Ltd. briefSummary: This is an open-label, phase II study evaluating the efficacy and safety of SHR-A1811 alone or in combination with Adebrelimab in Stage II-III ER Positive/HER2 Low Breast Cancer. Subjects will receive the neoadjuvant therapy of SHR-A1811 alone or in combination with Adebrelimab for six cycles, and then undergo surgery within 4 weeks after neoadjuvant therapy. Efficacy will be assessed every 2 cycles. conditions: ER Positive/HER2 Low Breast Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 93 type: ESTIMATED name: SHR-A1811 Injection + Adebrelimab Injection name: SHR-A1811 Injection + Adebrelimab Injection name: SHR-A1811 Injection measure: Total pathological complete response (tpCR: ypT0-is/ypN0) measure: Breast pathological complete response (bpCR：ypT0-is) measure: Residual cancer burden (RCB) measure: Best overall response rate (BORR) measure: Overall survival (OS) measure: Disease-free survival (DFS) measure: Event-free survival (EFS) measure: Health-related quality of life (HRQOL) (EORTC QLQ-C30) measure: Health-related quality of life (HRQOL) sex: FEMALE minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shengjing Hospital affiliated to China Medical University city: Shenyang state: Liaoning zip: 110004 country: China name: Nan Niu, MD role: CONTACT phone: +8618940256668 email: niunannancy@163.com name: Caigang Liu, MD role: PRINCIPAL_INVESTIGATOR lat: 41.79222 lon: 123.43278 hasResults: False
nctId: NCT06340217 id: WMT-GDP-RCT briefTitle: Washed Microbiota Transplantation for Diabetic Gastroparesis overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2029-01 date: 2029-07 date: 2024-04-01 date: 2024-04-17 name: The Second Hospital of Nanjing Medical University class: OTHER briefSummary: This is a randomized controlled trial to explore the efficacy and safety of washed microbiota transplantation (WMT) for diabetic gastroparesis (DGP) patients. conditions: Diabetic Gastroparesis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 46 type: ESTIMATED name: washed microbiota transplantation name: placebo measure: The proportion of DGP with symptom relief after the procedure. measure: The extent of change observed in GCSI of participants; measure: The extent of change observed in Gastroparesis Core Symptom Daily Diary (GCS-DD) of participants; measure: The extent of change observed in Patient Assessment of Upper Gastrointestinal Symptom Severity Index (PAGI-SYM) of participants; measure: The extent of change observed in Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life (PAGI-QoL) of participants; measure: The extent of change observed in electrogastrogram (EGG) of participants; measure: The extent of change observed in electrogastrogram (EGG) of participants; measure: The extent of change observed in gastrointestinal ultrasound (GIUS) of participants; measure: The incidence rate of adverse events; measure: The changes in gut microbiota composition and metabolites before and after treatment. sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University city: Nanjing state: Jiangsu zip: 210011 country: China lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06340204 id: PKUPH-EWS-03 briefTitle: Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma overallStatus: RECRUITING date: 2024-03-25 date: 2026-03-25 date: 2026-12-25 date: 2024-04-01 date: 2024-04-03 name: Peking University People's Hospital class: OTHER name: Peking University Shougang Hospital name: Shandong Cancer Hospital and Institute briefSummary: The investigators explored the safety and activity of weekly irinotecan liposomes in patients with relapsed and metastatic Ewing Sarcoma. conditions: Ewing Sarcoma studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 44 type: ESTIMATED name: Irinotecan Hydrochloride Liposome Injection measure: maximum tolerated dose (MTD) measure: Objective Response Rate (ORR) measure: Progression Free Survival (PFS) sex: ALL minimumAge: 8 Years maximumAge: 40 Years stdAges: CHILD stdAges: ADULT facility: Shandong Cancer Hospital and Institute status: NOT_YET_RECRUITING city: Jina state: Shandong zip: 250117 country: China name: Dongyuan Zhu, M.D. role: CONTACT email: 405683898@qq.com facility: Peking University Shougang Hospital status: NOT_YET_RECRUITING city: Beijing zip: 100043 country: China name: Jin GU, M.D. role: CONTACT email: jingu_1999@yahoo.com lat: 39.9075 lon: 116.39723 facility: Peking University People's Hospital status: RECRUITING city: Beijin zip: 100034 country: China name: Jie Xu, M.D. role: CONTACT phone: +86 15901040835 email: xujie@pkuph.edu.cn name: Xiaodong Tang, M.D. role: PRINCIPAL_INVESTIGATOR name: Lu Xie, M.D. role: SUB_INVESTIGATOR hasResults: False
nctId: NCT06340191 id: UJAPIlates1 briefTitle: Cueing and Pilates in Low Back Pain acronym: PIlatesuja overallStatus: COMPLETED date: 2023-05-02 date: 2024-02-20 date: 2024-02-26 date: 2024-04-01 date: 2024-04-01 name: University of Jaén class: OTHER briefSummary: The intervention involved two groups participating in supervised Pilates sessions, twice a week for 8 weeks, featuring a mix of mat and props-based exercises. Group 1 received additional cueing training to enhance alignment, muscle engagement, and movement technique, while Group 2 underwent the same Pilates regimen without this cueing component. conditions: Low Back Pain conditions: Pilates Exercise conditions: Pilates, Core Stability conditions: Mind-body Exercise studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 67 type: ACTUAL name: Pilates with cueing name: Pilates without cueing measure: Low back pain measure: Pain report measure: Fear of movement measure: Perceived Stress Scale measure: Pain self-efficacy measure: Patient Impression of Change measure: Body Awareness sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Jaen city: Jaen zip: 23071 country: Spain lat: 37.76922 lon: -3.79028 hasResults: False